New User:

Forgot your password?

Stock Market & Financial Investment News

Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
16:31 EDTIMGNOn The Fly: Closing Wrap
Subscribe for More Information
13:30 EDTIMGNImmunoGen downgraded to Market Perform from Outperform at Leerink
Leerink downgraded ImmunoGen to Hold following disappointing MARIANNE trial results.
13:16 EDTIMGNImmunoGen downgraded to Hold from Buy at Jefferies
Subscribe for More Information
12:27 EDTIMGNOn The Fly: Midday Wrap
Subscribe for More Information
09:28 EDTIMGNOn The Fly: Pre-market Movers
Subscribe for More Information
05:36 EDTIMGNImmunoGen reports Phase III MARIANNE study met non-inferiority endpoint
Subscribe for More Information
December 16, 2014
09:35 EDTCCRNCross Country Healthcare initiated with an Outperform at Avondale
Subscribe for More Information
08:35 EDTAMEDAmedisys names Paul Kusserow as CEO
Amedisys announced that its board has named Paul Kusserow as president and CEO and a member of the board. Kusserow will assume the role on December 16, from president and Interim CEO, Ronald LaBorde, who will remain a member of the senior management team in the role of vice chairman. LaBorde will also continue to serve as a member of the board. Kusserow was most recently vice chairman of Alignment Healthcare.
December 10, 2014
15:14 EDTIMGNImmunoGen volatility at high end of historic range
Subscribe for More Information
December 9, 2014
17:33 EDTCCRNCross Country Healthcare files to sell 3.52M shares of common stock for holders
December 7, 2014
12:53 EDTIMGNImmunoGen announces 'encouraging' IMGN529 clinical data
ImmunoGen announced the presentation of encouraging clinical findings with its IMGN529 experimental therapy for B-cell malignancies at the American Society of Hematology annual meeting. These include objective responses at doses that were generally well tolerated. ImmunoGenís IMGN529 is a potential new treatment for DLBCL and other non-Hodgkin lymphoma, NHL, subtypes. An ADC, it comprises an antibody that targets CD37, found on B-cell malignancies, with the potent cancer cell-killing agent, DM1, attached. The antibody serves to deliver the DM1 specifically to B cells to kill them and, based on preclinical research, also contributes anticancer activity. IMGN529 is currently in the dose-finding portion of a Phase I clinical trial, which assesses increasing doses of this experimental therapy in new groups of patients with relapsed/refractory NHL. Findings with the first doses evaluated were reported previously.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use